Latest news
Applied BioCode Reports Record Financial Results for the First Half of 2026; Revenue Increases 81% Year Over Year, Driven by Strong U.S. Molecular Diagnostics Growth - Business WireBusiness Wire · Mon, 10 Aug 2026 14:00:00 GMTDeadline Soon: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - Business WireBusiness Wire · Fri, 07 Aug 2026 18:40:00 GMTStockholder Alert: Robbins LLP Informs Investors of the Replimune Group, Inc. Class Action - Business WireBusiness Wire · Fri, 07 Aug 2026 03:32:00 GMTNASDAQ: MDLN Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Medline Inc. (NASDAQ: MDLN) Investors to Contact the Firm - Business WireBusiness Wire · Thu, 06 Aug 2026 20:43:00 GMTCAPR Shareholder Alert: Capricor Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky - Business WireBusiness Wire · Thu, 06 Aug 2026 14:11:00 GMTScholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Business WireBusiness Wire · Thu, 06 Aug 2026 11:00:00 GMTU.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season - Business WireBusiness Wire · Thu, 06 Aug 2026 10:45:00 GMTU.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 - Business WireBusiness Wire · Wed, 05 Aug 2026 22:10:00 GMT